 Connection
David Ivy to Familial Primary Pulmonary Hypertension
This is a "connection" page, showing publications David Ivy has written about Familial Primary Pulmonary Hypertension.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.114 |
|
|
|
-
Avitabile CM, Yung D, Handler S, Hopper RK, Fineman J, Freire G, Varghese N, Mullen MP, Krishnan US, Austin E, Silveira L, Ivy DD. Measurement of Physical Activity by Actigraphy in Infants and Young Children with Pulmonary Arterial Hypertension. J Pediatr. 2023 11; 262:113639.
Score: 0.194
-
Zhu N, Gonzaga-Jauregui C, Welch CL, Ma L, Qi H, King AK, Krishnan U, Rosenzweig EB, Ivy DD, Austin ED, Hamid R, Nichols WC, Pauciulo MW, Lutz KA, Sawle A, Reid JG, Overton JD, Baras A, Dewey F, Shen Y, Chung WK. Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults. Circ Genom Precis Med. 2018 04; 11(4):e001887.
Score: 0.134
-
Takatsuki S, Nakayama T, Ikehara S, Matsuura H, Ivy DD, Saji T. Pulmonary Arterial Capacitance Index Is a Strong Predictor for Adverse Outcome in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension. J Pediatr. 2017 01; 180:75-79.e2.
Score: 0.121
-
Douwes JM, Humpl T, Bonnet D, Beghetti M, Ivy DD, Berger RM. Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension: Current Clinical Practice From the TOPP Registry. J Am Coll Cardiol. 2016 Mar 22; 67(11):1312-23.
Score: 0.116
-
Ploegstra MJ, Ivy DD, Wheeler JG, Brand M, Beghetti M, Rosenzweig EB, Humpl T, Iriart X, Rouzic EM, Bonnet D, Berger RM. Growth in children with pulmonary arterial hypertension: a longitudinal retrospective multiregistry study. Lancet Respir Med. 2016 04; 4(4):281-90.
Score: 0.116
-
Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Galiè N, Ivy DD, Jaïs X, Miera O, Rosenzweig EB, Efficace M, Kusic-Pajic A, Beghetti M. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J Cardiol. 2016 Jan 01; 202:52-8.
Score: 0.112
-
Vorhies EE, Ivy DD. Drug treatment of pulmonary hypertension in children. Paediatr Drugs. 2014 Feb; 16(1):43-65.
Score: 0.100
-
Takatsuki S, Ivy DD. Current challenges in pediatric pulmonary hypertension. Semin Respir Crit Care Med. 2013 Oct; 34(5):627-44.
Score: 0.098
-
Takatsuki S, Parker DK, Doran AK, Friesen RH, Ivy DD. Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension. Pediatr Cardiol. 2013 Apr; 34(4):1006-12.
Score: 0.092
-
Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol. 2013 Jan; 48(1):27-34.
Score: 0.089
-
Ivy D. Advances in pediatric pulmonary arterial hypertension. Curr Opin Cardiol. 2012 Mar; 27(2):70-81.
Score: 0.088
-
Takatsuki S, Wagner BD, Ivy DD. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit Heart Dis. 2012 May-Jun; 7(3):259-67.
Score: 0.088
-
Barst RJ, McGoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation. 2012 Jan 03; 125(1):113-22.
Score: 0.086
-
Abman SH, Ivy DD. Recent progress in understanding pediatric pulmonary hypertension. Curr Opin Pediatr. 2011 Jun; 23(3):298-304.
Score: 0.083
-
Takatsuki S, Soep JB, Calderbank M, Ivy DD. Connective tissue disease presenting with signs and symptoms of pulmonary hypertension in children. Pediatr Cardiol. 2011 Aug; 32(6):828-33.
Score: 0.082
-
Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J. 2011 Mar; 37(3):665-77.
Score: 0.082
-
Ploegstra MJ, Ivy DD, Beghetti M, Bonnet D, Alehan D, Ablonczy L, Mattos S, Bowers D, Humpl T, Berger RMF. Long-term outcome of children with newly diagnosed pulmonary arterial hypertension: results from the global TOPP registry. Eur Heart J Qual Care Clin Outcomes. 2024 Jan 12; 10(1):66-76.
Score: 0.050
-
Schäfer M, Frank BS, Ivy DD, Mitchell MB, Collins KK, Jone PN, von Alvensleben JC. Repolarization Dispersion Is Associated With Diastolic Electromechanical Discoordination in Children With Pulmonary Arterial Hypertension. J Am Heart Assoc. 2022 03 15; 11(6):e024787.
Score: 0.044
-
Issapour A, Frank B, Crook S, Hite MD, Dorn ML, Rosenzweig EB, Ivy DD, Krishnan US. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience. Pediatr Pulmonol. 2022 03; 57(3):724-733.
Score: 0.043
-
Daly CM, Griffiths M, Simpson CE, Yang J, Damico RL, Vaidya RD, Williams M, Brandal S, Jone PN, Polsen C, Ivy DD, Austin ED, Nichols WC, Pauciulo MW, Lutz K, Nies MK, Rosenzweig EB, Hirsch R, Yung D, Everett AD. Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension. J Am Heart Assoc. 2021 10 19; 10(20):e021409.
Score: 0.043
-
Frank BS, Schafer M, Thomas TM, Haxel C, Ivy DD, Jone PN. Right Atrial Conduit Phase Emptying Predicts Risk of Adverse Events in Pediatric Pulmonary Arterial Hypertension. J Am Soc Echocardiogr. 2020 08; 33(8):1006-1013.
Score: 0.039
-
Di Maria MV, Younoszai AK, Mertens L, Landeck BF, Ivy DD, Hunter KS, Friedberg MK. RV stroke work in children with pulmonary arterial hypertension: estimation based on invasive haemodynamic assessment and correlation with outcomes. Heart. 2014 Sep; 100(17):1342-7.
Score: 0.026
-
Zijlstra WMH, Douwes JM, Rosenzweig EB, Schokker S, Krishnan U, Roofthooft MTR, Miller-Reed K, Hillege HL, Ivy DD, Berger RMF. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol. 2014 May 27; 63(20):2159-2169.
Score: 0.025
-
Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, Ivy DD. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014 May 13; 129(19):1914-23.
Score: 0.025
-
Barst RJ, Ivy DD, Foreman AJ, McGoon MD, Rosenzweig EB. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Am J Cardiol. 2014 Jan 01; 113(1):147-55.
Score: 0.025
-
Truong U, Fonseca B, Dunning J, Burgett S, Lanning C, Ivy DD, Shandas R, Hunter K, Barker AJ. Wall shear stress measured by phase contrast cardiovascular magnetic resonance in children and adolescents with pulmonary arterial hypertension. J Cardiovasc Magn Reson. 2013 Sep 13; 15:81.
Score: 0.024
-
Siehr SL, Ivy DD, Miller-Reed K, Ogawa M, Rosenthal DN, Feinstein JA. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics. J Heart Lung Transplant. 2013 May; 32(5):546-52.
Score: 0.024
-
Krishnan U, Takatsuki S, Ivy DD, Kerstein J, Calderbank M, Coleman E, Rosenzweig EB. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. Am J Cardiol. 2012 Dec 01; 110(11):1704-9.
Score: 0.023
-
Takatsuki S, Nakayama T, Jone PN, Wagner BD, Naoi K, Ivy DD, Saji T. Tissue Doppler imaging predicts adverse outcome in children with idiopathic pulmonary arterial hypertension. J Pediatr. 2012 Dec; 161(6):1126-31.
Score: 0.022
-
Hill KD, Lim DS, Everett AD, Ivy DD, Moore JD. Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry. Catheter Cardiovasc Interv. 2010 Nov 15; 76(6):865-73.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|